Blockchain Registration Transaction Record

NanoViricides Advances Broad-Spectrum Antiviral NV-387 Toward Phase 2 Trials

NanoViricides advances NV-387 broad-spectrum antiviral targeting MPox, influenza, coronaviruses & RSV. Phase 2 trials planned for 2025-2026 with potential BARDA funding opportunities.

The development of NV-387 represents a significant advancement in antiviral therapeutics with potential implications for global public health. Broad-spectrum antivirals that can target multiple viruses simultaneously could revolutionize how we respond to emerging infectious disease threats, potentially providing rapid-response treatments during future pandemics. For healthcare systems, such medications could reduce the need for virus-specific testing before treatment initiation, streamlining clinical workflows. For patients, a single medication effective against multiple respiratory viruses could simplify treatment regimens and improve outcomes. The technology's mechanism of preventing viral entry into cells rather than targeting replication could also reduce the likelihood of resistance development, addressing a major limitation of current antiviral therapies. Success in this program could establish a new paradigm for antiviral drug development and pandemic preparedness.